Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off

NCT00601978 | Withdrawn Phase 4 DMC

• 1 other identifier: CELC200AUS15
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study will evaluate the effects of immediate release (IR) carbidopa levodopa versus the effects of immediate-release carbidopa/levodopa on ERP parameters in patients with idiopathic PD.

Conditions

Parkinson's Disease

Keywords

Parkinson's disease; carbidopa/levodopa/entacapone; carbidopa/levodopa; non-motor symptoms; event-related potential; ERP; EEG; electroencephalogram

Outcome Measures

Primary Outcomes (1)

• To evaluate the mean latency of the P300 component of the event-related potentials (ERPs) at four hours post study-drug administration

Secondary Outcomes (3)

• Mean latency of the P300 component of ERPs at pre-dose and 1 hours post-dose study drug administration

• Mean latency of the N100 component of ERPs at pre-dose, 1 hour post-dose and 4 hours post-dose study drug administration

• Pharmacokinetics at 9.25 and 12.55 hours post dose

Study Arms (2)

1

ACTIVE COMPARATOR

Immediate-Release Carbidopa/Levodopa

Drug: carbidopa/levodopa

2

ACTIVE COMPARATOR

Carbidopa/Levodopa/Entacapone

Drug: Carbidopa/Levodopa/Entacapone

Interventions

carbidopa/levodopa DRUG

1

Carbidopa/Levodopa/Entacapone DRUG

Also known as: Stalevo

2

Eligibility Criteria

• Age: 45 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female patients aged 45 to 75 years (inclusive)
• Patients with an MMSE score of at least 25 at the screening visit.
• Patients who experience EODWO, which is the re-emergence of PD symptoms during the waking hours, as determined by a WOQ-9 score of at least one motor symptom of wearing off
• Patients taking a stable dose of immediate-release carbidopa/levodopa for at least 4 weeks prior to randomization, at an equivalent total daily dose of levodopa between 300 to 600 mg/day.
• Patients who, in the investigator's judgement, are capable of satisfying the requirements of the protocol
• Patients who are willing and able to give written informed consent according to legal requirements.

You may not qualify if:

• Diagnosis of secondary parkinsonism, atypical Parkinson's disease, or history, signs, or symptoms suggesting these diagnoses.
• Unstable Parkinson's disease as determined by the investigator.
• Disabling dyskinesia (a score of \>2 on the Unified Parkinson's Disease Rating Scale \[UPDRS\] question #32, or a score of \>2 on UPDRS question #33).
• Treatment with carbidopa/levodopa controlled-release or extended-release formulations (bedtime administration is acceptable). The use of controlled-release carbidopa/levodopa is not allowed on the evening before the visits in which efficacy assessments occur.
• Concomitant or previous treatment with certain medications or supplements as specified in the protocol.
• Patients who are unable to comply with the dosing requirements of the protocol, such that the first dose of study medication will be taken after the time of the first EEG and the second dose will be taken after completion of the third EEG.
• Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR; diagnosis of 1. dementia (of any cause); 2. moderate or severe major depression, present independent from the time of first diagnosis of PD, as defined by a QIDS-SR16 score of \> 15; or 3. generalized anxiety disorder or panic disorder if made prior to the diagnosis of PD.
• DSM-IV-TR diagnosis of alcohol or substance abuse (excluding nicotine or caffeine) during the 3 months prior to randomization) or alcohol or substance dependence (excluding nicotine or caffeine) during the 6 months prior to randomization. Alcohol should be avoided within the 12 hours preceding the Week 6 and Week 12 visits.
• Nicotine use of \>5 cigarettes (or equivalent in other forms of administration) per day. Nicotine use will not be permitted on the day of the Week 6 and Week 12 visits.
• Ingestion of \>4 caffeinated beverages (or equivalent in other forms of administration) per day.
• History of major head injury, including skull fracture or a penetrating head injury, or a history of brain surgery.
• Past or current treatment by deep brain stimulation.
• History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.
• Hearing loss or impairment that may prevent reliability of test results using auditory evoked potentials.

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

MeSH Terms

Conditions

Parkinson Disease

Interventions

carbidopa, levodopa drug combination; Stalevo

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 11, 2008
• First Posted: January 28, 2008
• Study Start: August 1, 2008
• Primary Completion: November 1, 2009
• Study Completion: November 1, 2009
• Last Updated: April 30, 2012

Record last verified: 2012-04